References
- Labib A, Ju T, Vander Does A, Yosipovitch G. Immunotargets and therapy for prurigo nodularis. Immunotargets Ther. 2022;11:11–21. doi:10.2147/ITT.S316602
- Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456. doi:10.1007/s40257-019-00445-7
- Paller AS, Beck LA, Blauvelt A, et al. Infections in adolescents and children treated with dupilumab in pediatric clinical trials for atopic dermatitis – a pooled analysis of trial data. Pediatr Dermatol. 2022;39(2):187–196. doi:10.1111/pde.14909
- Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther. 2023;40:367–380. doi:10.1007/s12325-022-02322-y
- Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023. doi:10.1038/s41591-023-02320-9
- Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol. 2020;140(1):191–202. doi:10.1016/j.jid.2019.05.024
- Dupixent®. U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s044lbl.pdf. Accessed May 15, 2023.